A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis

Schizophrenia Research

Volumn 155, Issue 1-3, 2014, Pages 52-58

  Kimura, Hiroshi ^a   Kanahara, Nobuhisa ^a   Komatsu, Naoya ^b   Ishige, Minoru ^c   Muneoka, Katsumasa ^d   Yoshimura, Masayuki ^e   Yamanaka, Hiroshi ^a,f   Suzuki, Tomotaka ^a,g   Komatsu, Hideki ^a,h   Sasaki, Tsuyoshi ^a   Hashimoto, Tasuku ^a   Hasegawa, Tadashi ^a   Shiina, Akihiro ⁱ   Ishikawa, Masatomo ^a   Sekine, Yoshimoto ^a,h   Shiraishi, Tetsuya ^a   Watanabe, Hiroyuki ^a,j   Shimizu, Eiji ^a   Hashimoto, Kenji ^a   Iyo, Masaomi ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Dowa Kai Chiba Hospital   (Japan)

^c Department of Psychiatry Satsuki kai Sodegaura satsukidai Hospital   (Japan)

^d Department of Psychiatry Gakuji kai Kimura Hospital   (Japan)

^e Doujin kai Kisaradzu Hospital   (Japan)

^f Chiba Psychiatric Medical Center   (Japan)

^g Koutokukai   (Japan)

^h Department of Psychiatry Choshi Kokoro Clinic   (Japan)

ⁱ CHIBA UNIVERSITY HOSPITAL   (Japan)

^j Department of Psychiatry Chiba University Hospital ^*  (Japan)

more..

Author keywords

Antipsychotics; Dopamine D2 receptor; Occupancy rate; Tolerance

Indexed keywords

OLANZAPINE; QUETIAPINE; RISPERIDONE; DOPAMINE; NEUROLEPTIC AGENT;

ADJUVANT THERAPY; ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOPAMINE SUPERSENSITIVITY PSYCHOSIS; DRUG EFFICACY; DRUG RESISTANCE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; SCHIZOPHRENIA; TREATMENT DURATION; ADOLESCENT; AGED; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; FOLLOW UP; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PSYCHOLOGICAL RATING SCALE; PSYCHOTIC DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOPAMINE; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899491639     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.02.022     Document Type: Article

References (46)

1. Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr. Res. 1991, 5:21-33.
2. Chouinard G., Chouinard V.A. Atypical antipsychotics. CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother. Psychosom. 2008, 77:69-77.
3. Chouinard G., Margolese H.C. Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr. Res. 2005, 76:247-265.
4. Chouinard G., Jones B.D., Annable L. Neuroleptic-induced supersensitivity psychosis. Am. J. Psychiatry 1978, 135:1409-1410.
5. Chouinard G., Annable L., Ross-Chouinard A., et al. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J. Clin. Psychopharmacol. 1988, 8(4 Suppl.):21S-26S.
6. Correll C.U., Leucht S., Kane J.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry 2004, 161:414-425.
7. Eerdenkens M., Hove I.V., Remmerie B., Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr. Res. 2004, 70:91-100.
8. Fakra E., Azorin J.M. Clozapine for the treatment of schizophrenia. Expert. Opin. Pharmacother. 2012, 13:1923-1935.
9. Fallon P., Dursun S.M. A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis. J. Psychopharmacol. 2011, 25:755-762.
10. First M.B., Spitzer R.I., Gibbon M., et al. Structured Clinical Interview for DSM-IV Axis I Disorders/Patient Edition (SCID-I/P, Version 2.0) 1995, Biometrics Research Department, New York State Psychiatric Institute, New York.
11. Freedman R. Schizophrenia. N. Engl. J. Med. 2003, 349:1738-1749.
12. Galderisi S., Maj M. Deficit schizophrenia: an overview of clinical, biological and treatment aspects. Eur. Psychiatry 2009, 24:493-500.
13. Garfield S., Clifford S., Eliasson L., Barber N., Willson A. Suitability of measures of self-reported medication adherence for routine clinical use: a systematic review. BMC Med. Res. Methodol. 2011, 11:149.
14. Gueorguieva R., Krystal J.H. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch. Gen. Psychiatry 2004, 61:307-317.
15. Hashimoto K. Glycine transporter-1: a new potential therapeutic target for schizophrenia. Curr. Pharm. Des. 2011, 17:112-120.
16. Inoue A., Miki S., Seto M., et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur. J. Pharmacol. 1997, 321:105-111.
17. Insel T.R. Rethinking schizophrenia. Nature 2010, 468:187-193.
18. Iyo M., Tadokoro S., Kanahara N., et al. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J. Clin. Psychopharmacol. 2013, 33:398-404.
19. Juarez-Reyes M.G., Shumway M., Battle C., Bacchetti P., Hansen M.S., Hargreaves W.A. Clozapine eligibility: the effect of stringent ariteria on ethnic, gender and age subgroups of schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 1996, 20:1341-1352.
20. Kanahara N., Sekine Y., Haraguchi T., et al. Orbitofrontal cortex abnormality and deficit schizophrenia. Schizophr. Res. 2013, 143:246-252.
21. Kane J., Honigfeld G., Singer J., Melzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45:789-796.
22. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D (2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 2000, 157:514-520.
23. Kelly D.L., Feldman S., Boggs D.L., Gale E., Conley R.R. Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia. Compr. Psychiatry 2010, 51:298-302.
24. Kimura H., Kanahara N., Watanabe H., et al. Potential treatment strategy of risperidone long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis. Schizophr. Res. 2013, 145:130-131.
25. Kirkpatrick B., Alphs L., Buchanan R.W. The concept of supersensitivity psychosis. J. Nerv. Ment. Dis. 1992, 180:265-270.
26. Li C.R., Chung Y.C., Park T.W., et al. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug. World J. Biol. Psychiatry 2009, 10:919-924.
27. Lieberman J., Jody D., Geisler S., et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch. Gen. Psychiatry 1993, 50:369-376.
28. Miyamoto S., Miyake N., Jarskog L.F., Fleischhacker W.W., Lieberman J.A. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol. Psychiatry 2012, 17:1206-1227.
29. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersenstivity psychosis) and withdrawal-related relapse. Acta Psychiatr. Scand. 2006, 114:3-13.
30. Oehl M., Hummer M., Fleichhacker W.W. Compliance with antipsychotic treatment. Acta Psychiatr. Scand. 2000, 407:83-86. (Suppl.).
31. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 1962, 10:799-812.
32. Procyshyn R.M., Barr A.M., Flynn S., Schenk C., Ganesan S., Honer W.G. Long-acting injectable risperidone in treatment refractory patients: a 14-week open-label pilot study. Schizophr. Res. 2010, 123:273-275.
33. Remington G., Mamo D., Labelle A., et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am. J. Psychiatry 2006, 163:396-401.
34. Robinson D., Woerner M.G., Alvir J.M., et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry 1999, 56:241-247.
35. Rosenheck R., Dunn L., Peszke M., et al. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Am. J. Psychiatry 1999, 156:88-93.
36. Samaha A.N., Seeman P., Stewart J., et al. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J. Neurosci. 2007, 27:2979-2986.
37. Samaha A.N., Reckless G.E., Seeman P., et al. Less is more: antipsychotic drug effects are greater with transient rather continuous delivery. Biol. Psychiatry 2008, 64:145-152.
38. Sasaki H., Hashimoto K., Inada T., Fukui S., Iyo M. Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol. Eur. J. Pharmacol. 1995, 282:71-76.
39. Sasaki H., Hashimoto K., Maeda Y., Inada T., Kitao Y., Fukui S., Iyo M. Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats. Life Sci. 1995, 56:L443-L447.
40. Szymanski S.R., Cannon T.D., Gallacher F., Erwin R.J., Gur R.E. Course of treatment response in first-episode and chronic schizophrenia. Am. J. Psychiatry 1996, 153:519-525.
41. T.S.S.R.Group The Scottish first episode schizophrenia study. VIII. Five-year follow-up: clinical and psychosocial findings. Br. J. Psychiatry 1992, 161:496-500.
42. Tadokoro S., Okamura N., Sekine Y., et al. Chronic treatment with aripipurazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr. Bull. 2012, 38:1012-1020.
43. Tandon R. Antipsychotics in the treatment of schizophrenia: an overview. J. Clin. Psychiatry 2011, 72(Suppl. 1):4-8.
44. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr. Res. 2009, 110:1-23.
45. Volonteri L.S., Cerveri G., De Gaspari I.F., et al. Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients. Psychopharmacology 2010, 210:489-497.
46. Zipursky R.B., Reilly T.J., Murray R.M. The myth of schizophrenia as a progressive brain disease. Schizophr. Bull. 2013, 39:1363-1372.